Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<p>M3 Inc. reported its 2QFY03/21 results last week. Both revenue and operating profit grew significantly compared to the same quarter last year by 28.5% YoY and 65.8% YoY respectively. At the same time, both revenue and OP beat consensus estimates by 7.2% and 26.6% respectively.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/170/077/original/image_87776018731604867251678.png?1604867253" class="editor-image img-responsive" data-smartkarma-image-id="170077"></figure><div class="content-caption"><em>Source: Company Disclosures, Cap IQ</em></div><p>We discuss the details below.</p>

M3 Inc. reported its 2QFY03/21 results last week. Both revenue and operating profit grew significantly compared to the same quarter last year by 28.5% YoY and 65.8% YoY respectively. At the same time, both revenue and OP beat consensus estimates by 7.2% and 26.6% respectively.Source: Company Disclosures, Cap IQWe discuss the details below.

M3 Inc: Strong Earnings Momentum Continues

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Thematic (Sector/Industry)

<p style="text-align: center;"><strong>• FORWARD NET INCOME &lt;¥20 TRILLION •</strong></p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/639/original/2020-11-01_11-41-42.png?1604198522" class="editor-image img-responsive" data-smartkarma-image-id="168639"></figure><div class="content-caption">Source for all charts &amp; tables: Japan Analytics</div></section><p><strong>&lt;¥20T</strong> - Aggregate earnings for Japan's listed companies are in their eighth successive quarter of decline. Forecast net income for the year ended December-to-March is now below ¥20 trillion and 60% lower than the 2019 peak of ¥48.5 trillion.  Despite the recent correction, the forward market multiple is at a new post-GFC high. On a more optimistic note, for many larger capitalisation companies, there has been a quarter-on-quarter improvement in sales and operating income although the year-on-year changes are still negative. As a result, our momentum-based Results Score and Forecast/Revision Score have both turned upwards.</p><section class="figure"><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/640/original/2020-11-01_13-06-28.png?1604203602" class="editor-image img-responsive" data-smartkarma-image-id="168640"></figure></section><p><strong>CAVEATS</strong> - Curbing any enthusiasm embedded in the previous sentence, would however note:-</p>
<ul>
<li>The upturn in momentum is concentrated mainly in large-cap companies which are over-represented in our data series due to cap-weighting. Significant cost-cutting has helped improve margins but has also reduced the revenues of smaller companies further down the supply chain. This divergence will be covered in an upcoming Insight.</li>
<li>The resurgence of COVID-19 and the daily new peaks in confirmed cases has not yet spread to Japan. However, with much of Europe re-entering 'lockdown', we expect the current quarter will not repeat the upturn seen in the second, and therefore, many companies will not meet their full-year targets many of which were recently revised up.</li>
<li>As a result of central bank liquidity creation, much of the recovery in earning that will occur over the next several years has already been discounted in share prices. Although the policy prescriptions that we noted in<a href="https://www.smartkarma.com/insights/japan-in-the-suga-era-policy-priorities-suga-stocks" target="_blank" data-smartkarma-citation="insights:43773" rel="noopener"> Japan in the Suga Era</a> will benefit many areas of the economy, Japan remains overweighted in industries that face significant disruption and disintermediation.</li>
</ul>
<section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/670/original/2020-11-01_14-52-47.png?1604209987" class="editor-image img-responsive" data-smartkarma-image-id="168670"></figure></section><section class="figure"></section><p><strong>BoJ</strong> -  Although the amounts are 30% smaller, this week was the first time since the second week of May that the Bank of Japan has purchased ETFs three days in a row. Despite growing <a href="http://www.asahi.com/ajw/articles/13863217" target="_blank" rel="noopener">attention</a> being paid to the scale and breadth of public sector ownership of Japanese equities, BoJ Governor Kuroda has PM Suga's support for continued interventions. We expect the cumulative total purchases to reach 6% of Total Market Value before the end of the fiscal year. </p></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/672/original/2020-11-01_15-05-07.png?1604210720" class="editor-image img-responsive" data-smartkarma-image-id="168672"></figure></section><hr><p style="text-align: center;"><strong>• MARKET TECHNICALS •</strong></p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/678/original/2020-11-01_15-15-20.png?1604211336" class="editor-image img-responsive" data-smartkarma-image-id="168678"></figure></section><p><strong>14-DAY RSI</strong> - The Relative Strength Index is close to a new eight-month low but is yet to reach the 'buying-zone' of less than 25.</p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/681/original/2020-11-01_15-58-15.png?1604213912" class="editor-image img-responsive" data-smartkarma-image-id="168681"></figure></section><p><strong>25-DAY TORAKU</strong> - This advance/decline indicator is suggesting that a selling climax is likely to occur this month. Panic lows are at levels below 70 - the COVID-19 low of 45 was the lowest level in over twenty years.</p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/682/original/2020-11-01_16-09-21.png?1604214610" class="editor-image img-responsive" data-smartkarma-image-id="168682"></figure></section><p><strong>HIGH-LOW %</strong> - Having only just turned negative, this ratio is a long way from the 10-15% level needed to form a buy signal.</p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/683/original/2020-11-01_16-12-30.png?1604214765" class="editor-image img-responsive" data-smartkarma-image-id="168683"></figure></section><p><strong>MCCLELLAN SUMMATION</strong> - Similarly, the McClellan A/D Summation is neutral and well above the -4,000 buying zone.</p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/684/original/2020-11-01_16-15-15.png?1604214933" class="editor-image img-responsive" data-smartkarma-image-id="168684"></figure></section><p><a href="https://www.dropbox.com/s/kwe54zk9yrxmtan/2020-11-01_16-15-15.png?dl=0" target="_blank" rel="noopener">MOVING AVERAGES</a> -  Lastly, the Total Market Value is approaching the support level of the 200-Day moving average. If breached, a 50-Day/200-Day negative crossover is likely, extending this correction to below ¥600 trillion.</p><hr><p style="text-align: center;"><strong>• SECTOR RESULTS &amp; REVISION SCORES TIMELINE •</strong></p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/686/original/2020-11-01_16-26-10.png?1604215582" class="editor-image img-responsive" data-smartkarma-image-id="168686"></figure></section><section class="figure"></section><p><strong>TIMELINE</strong> - The results 'season' is now in full 'swing'. To date, the Sectors with the strongest earnings momentum are <strong>Machinery</strong>, <strong>Retail</strong>,<strong> Electrical Equipmen</strong>t, and <strong>Other Materials</strong>. The weakest are <strong>Other Commerical Products</strong>,<strong> Information Technology</strong>, <strong>Real Estate</strong>, and <strong>Energy</strong>. Only four Sectors have a positive Score, lead by<strong> Internet Content &amp; Services</strong>. </p><hr><p style="text-align: center;"><strong>• BEST &amp; WORST •</strong></p><div><p>Our best and worst pairings from Friday's announcements are <a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a> and <a href="https://www.smartkarma.com/entities/lasertec-corp" target="_blank" data-smartkarma-citation="entities:4126:1" rel="noopener">Lasertec (6920 JP)</a> for the best and <a href="https://www.smartkarma.com/entities/pola-orbis-holdings-inc" target="_blank" data-smartkarma-citation="entities:2287:1" rel="noopener">Pola Orbis (4927 JP)</a> and <a href="https://www.smartkarma.com/entities/mitsui-co-ltd" target="_blank" data-smartkarma-citation="entities:20799:1" rel="noopener">Mitsui (8031 JP)</a> for the worst. </p></div><section class="figure"><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/688/original/2020-11-01_16-47-56.png?1604216889" class="editor-image img-responsive" data-smartkarma-image-id="168688"></figure></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/689/original/2020-11-01_16-53-04.png?1604217196" class="editor-image img-responsive" data-smartkarma-image-id="168689"></figure></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/690/original/2020-11-01_16-58-22.png?1604217564" class="editor-image img-responsive" data-smartkarma-image-id="168690"></figure></section><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/168/691/original/2020-11-01_16-59-54.png?1604217609" class="editor-image img-responsive" data-smartkarma-image-id="168691"></figure></section><div>
<hr>
<p style="text-align: center;"><strong>DAILY STATS</strong></p>
<p style="text-align: left;">Results are evenly split between positive and neutral, however, TTM revenues are still falling by 5% and operating margins are on average 1.5 points lower. 60% of annual revisions are negative and the average change in score is a decline of 4 points.</p>
</div>
<hr>
<div><p style="text-align: center;"><strong>407 Quarterly Results</strong></p></div>
<div><ul style="list-style-type: disc;">
<li><p><strong>Results Score:</strong> 42% Positive / 6% Neutral / 42% Negative</p></li>
<li><p><strong>Average Results Score Change:</strong> -1.2 points</p></li>
<li><p><strong>Average % Change in Revenue:</strong> -7.9% Quarter YoY / -5.2% Rolling TTM YoY </p></li>
<li><p><strong>Average Operating Profit Margin Change</strong>: -1.5ppt</p></li>
<li><p><strong>Percentage Making Quarterly Losses:</strong> 20%</p></li>
</ul></div>
<hr>
<div><p style="text-align: center;"><strong>197 Annual • 45 Interim Forecasts/Revisions</strong></p></div>
<div><ul style="list-style-type: disc;">
<li><p><strong>Annual Forecast/Revision Score:</strong> 31% Positive / 9% Neutral / 59% Negative</p></li>
<li><p><strong>Interim Forecast/Revision Score Change:</strong> 47% Positive / 11% Neutral / 42% Negative</p></li>
<li><p><strong>Average Forecast/Revision Score Change:</strong> -4.0 points</p></li>
</ul></div></section>

• FORWARD NET INCOME &lt;¥20 TRILLION •Source for all charts &amp; tables: Japan Analytics&lt;¥20T - Aggregate earnings for Japan's listed companies are in their eighth successive quarter of decline. Forecast net income for the year ended December-to-March is now below ¥20 trillion and 60% lower than the 2019 peak of ¥48.5 trillion.  Despite the recent correction, the forward market multiple is at a new post-GFC high. On a more optimistic note, for many larger capitalisation companies, there has been a quarter-on-quarter improvement in sales and operating income although the year-on-year changes are still negative. As a result, our momentum-based Results Score and Forecast/Revision Score have both turned upwards.CAVEATS - Curbing any enthusiasm embedded in the previous sentence, would however note:-

The upturn in momentum is concentrated mainly in large-cap companies which are over-represented in our data series due to cap-weighting. Significant cost-cutting has helped improve margins but has also reduced the revenues of smaller companies further down the supply chain. This divergence will be covered in an upcoming Insight.
The resurgence of COVID-19 and the daily new peaks in confirmed cases has not yet spread to Japan. However, with much of Europe re-entering 'lockdown', we expect the current quarter will not repeat the upturn seen in the second, and therefore, many companies will not meet their full-year targets many of which were recently revised up.
As a result of central bank liquidity creation, much of the recovery in earning that will occur over the next several years has already been discounted in share prices. Although the policy prescriptions that we noted in Japan in the Suga Era will benefit many areas of the economy, Japan remains overweighted in industries that face significant disruption and disintermediation.

BoJ -  Although the amounts are 30% smaller, this week was the first time since the second week of May that the Bank of Japan has purchased ETFs three days in a row. Despite growing attention being paid to the scale and breadth of public sector ownership of Japanese equities, BoJ Governor Kuroda has PM Suga's support for continued interventions. We expect the cumulative total purchases to reach 6% of Total Market Value before the end of the fiscal year. • MARKET TECHNICALS •14-DAY RSI - The Relative Strength Index is close to a new eight-month low but is yet to reach the 'buying-zone' of less than 25.25-DAY TORAKU - This advance/decline indicator is suggesting that a selling climax is likely to occur this month. Panic lows are at levels below 70 - the COVID-19 low of 45 was the lowest level in over twenty years.HIGH-LOW % - Having only just turned negative, this ratio is a long way from the 10-15% level needed to form a buy signal.MCCLELLAN SUMMATION - Similarly, the McClellan A/D Summation is neutral and well above the -4,000 buying zone.MOVING AVERAGES -  Lastly, the Total Market Value is approaching the support level of the 200-Day moving average. If breached, a 50-Day/200-Day negative crossover is likely, extending this correction to below ¥600 trillion.• SECTOR RESULTS &amp; REVISION SCORES TIMELINE •TIMELINE - The results 'season' is now in full 'swing'. To date, the Sectors with the strongest earnings momentum are Machinery, Retail, Electrical Equipment, and Other Materials. The weakest are Other Commerical Products, Information Technology, Real Estate, and Energy. Only four Sectors have a positive Score, lead by Internet Content &amp; Services. • BEST &amp; WORST •Our best and worst pairings from Friday's announcements are M3 Inc (2413 JP) and Lasertec (6920 JP) for the best and Pola Orbis (4927 JP) and Mitsui (8031 JP) for the worst. 

DAILY STATS
Results are evenly split between positive and neutral, however, TTM revenues are still falling by 5% and operating margins are on average 1.5 points lower. 60% of annual revisions are negative and the average change in score is a decline of 4 points.


407 Quarterly Results

Results Score: 42% Positive / 6% Neutral / 42% Negative
Average Results Score Change: -1.2 points
Average % Change in Revenue: -7.9% Quarter YoY / -5.2% Rolling TTM YoY 
Average Operating Profit Margin Change: -1.5ppt
Percentage Making Quarterly Losses: 20%


197 Annual • 45 Interim Forecasts/Revisions

Annual Forecast/Revision Score: 31% Positive / 9% Neutral / 59% Negative
Interim Forecast/Revision Score Change: 47% Positive / 11% Neutral / 42% Negative
Average Forecast/Revision Score Change: -4.0 points


🇯🇵 JAPAN • Market Update & Results & Revisions 10/​​​​​​​​​​​​​​​​​​​​​30

Equity Capital Markets

JD Health International  / Equity Capital Markets

<p>JD Health International, the largest online healthcare platform and retail pharmacy in China has filed for an IPO to list its shares on the Hong Kong Stock Exchange. The company is backed by the Chinese online retail giant JD.Com, and is planning to raise about US$3bn through the IPO.</p><p>In this insight, we examine the company’s business model and its financials.</p>

JD Health International, the largest online healthcare platform and retail pharmacy in China has filed for an IPO to list its shares on the Hong Kong Stock Exchange. The company is backed by the Chinese online retail giant JD.Com, and is planning to raise about US$3bn through the IPO.In this insight, we examine the company’s business model and its financials.

JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic

<p><a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a>  provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates m3.com, its key platform alongside several other websites and platforms aimed at providing different services such as information provision, marketing services, medical health records and career solutions for physicians and medical practitioners.</p><p>The company share price has more than doubled to JPY6,380 per share (from JPY2,921 on 26<sup>th</sup> March 2020) since we last wrote on the company. In this insight, we examine the key catalysts behind the company’s share price rally and the valuation.</p>

M3 Inc (2413 JP)  provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates m3.com, its key platform alongside several other websites and platforms aimed at providing different services such as information provision, marketing services, medical health records and career solutions for physicians and medical practitioners.The company share price has more than doubled to JPY6,380 per share (from JPY2,921 on 26th March 2020) since we last wrote on the company. In this insight, we examine the key catalysts behind the company’s share price rally and the valuation.

M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/693/original/2020-09-14_09-50-37.png?1600044664" class="editor-image img-responsive" data-smartkarma-image-id="158693"></figure><div class="content-caption">Source for all charts &amp; tables except as stated: Japan Analytics</div><p><strong>EQUITY-DRIVEN</strong> - Japan's aggregate Shareholders' Equity has appreciated by 45% since 2014 - an annual rate of 5.5% and has been one of the key achievements of the 'Abe era'. For the five years before 2012, Shareholders Equity was unchanged, buffeted by the 2008/9 financial crisis and the 3/11.  Although the equity market has responded well to the change in reserves, Japan's PBR has remained within a range of 1.05 to 1.38 over the last decade and is unchanged compared to 2010. In prior post-bubble 'lost' decades, the average PBR was 1.8 times. In other markets, the rise of intangible assets has called the use of Book/Price as a metric and the S&amp;P 500 PBR is now almost three times that of the Japan aggregate having bottomed at 1.78 in March 2009.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/694/original/File%202020-09-14%2010%2007%2037.jpeg?1600045681" class="editor-image img-responsive" data-smartkarma-image-id="158694"></figure><div class="content-caption">Source: multpl.com</div><p><strong>BOOK VALUE PER SHARE </strong>- In this Insight, we shall look at Japan's larger-cap companies (current market value &gt;¥100 billion) through the 'lens' of book value per share. Our focus will be less on the 'winners' and 'losers' than on those companies that have seen the least change in 'BVPS' over the last seven years. Our share count excludes treasury shares which is to the benefit of companies such as <a href="https://www.smartkarma.com/entities/nippon-telegraph-telephone-corporation" target="_blank" data-smartkarma-citation="entities:623:1" rel="noopener">NTT (9432 JP)</a> which has seen a 20% reduction in Net Shares Outstanding, but only a 9% increase in Shareholders' Equity. A BVPS growth metric does, however, flatter serial issuers of equity with declining share prices, such as <a href="https://www.smartkarma.com/entities/sosei-group-corp" target="_blank" data-smartkarma-citation="entities:770:1" rel="noopener">Sosei (4565 JP)</a>.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/696/original/2020-09-14_10-26-48.png?1600046818" class="editor-image img-responsive" data-smartkarma-image-id="158696"></figure><p><strong>WINNERS</strong> - As many may ask and for the record, our 'winning' thirty companies contains many of Japan's best-performing businesses and 'priciest 'stocks, such as <a href="https://www.smartkarma.com/entities/monotaro-co-ltd" target="_blank" data-smartkarma-citation="entities:15441:1" rel="noopener">Monotaro (3064 JP)</a>, <a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 (2413 JP)</a>, <a href="https://www.smartkarma.com/entities/gmo-payment-gateway-inc" target="_blank" data-smartkarma-citation="entities:1492:1" rel="noopener">GMO Payment Gateway (3769 JP)</a>, and <a href="https://www.smartkarma.com/entities/kobe-bussan-co-ltd" target="_blank" data-smartkarma-citation="entities:4701:1" rel="noopener">Kobe Bussan (3038 JP)</a>. Some of the more surprising entries are <a href="https://www.smartkarma.com/entities/mixi-inc" target="_blank" data-smartkarma-citation="entities:602:1" rel="noopener">mixi (2121 JP)</a> and <a href="https://www.smartkarma.com/entities/tokyo-electric-power-co-inc" target="_blank" data-smartkarma-citation="entities:15457:1" rel="noopener">Tokyo Electric Power (9501 JP)</a>.  As an equally-weighted portfolio, this group has outperformed by 30% over one year and by 11% over the last three months.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/697/original/2020-09-14_10-33-13.png?1600047204" class="editor-image img-responsive" data-smartkarma-image-id="158697"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/698/original/2020-09-14_10-33-41.png?1600047231" class="editor-image img-responsive" data-smartkarma-image-id="158698"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/701/original/2020-09-14_10-47-56.png?1600048087" class="editor-image img-responsive" data-smartkarma-image-id="158701"></figure><p><strong>LOSERS</strong> - Our list of losers, who have collectively underperformed by 9% over one year, have many of Japan's weaker business models (shipping, oil &amp; gas, paper, copiers, gaming machines. The list also features some of the less-astute management 'teams' (<a href="https://www.smartkarma.com/entities/toshiba-corp" target="_blank" data-smartkarma-citation="entities:637:1" rel="noopener">Toshiba (6502 JP)</a>, <a href="https://www.smartkarma.com/entities/nissan-motor-co-ltd" target="_blank" data-smartkarma-citation="entities:72:1" rel="noopener">Nissan (7201 JP)</a>, <a href="https://www.smartkarma.com/entities/kirin-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:16977:1" rel="noopener">Kirin (2503 JP)</a>, <a href="https://www.smartkarma.com/entities/lixil-group-corp" target="_blank" data-smartkarma-citation="entities:454:1" rel="noopener">Lixil (5938 JP)</a>, and <a href="https://www.smartkarma.com/entities/aeon-co-ltd" target="_blank" data-smartkarma-citation="entities:3:1" rel="noopener">Aeon (8267 JP)</a>).  Also among the latter are two medical-related business - the now remained <a href="https://www.smartkarma.com/entities/h-u-group-holdings-inc" target="_blank" data-smartkarma-citation="entities:16580:1" rel="noopener">H.U. Group (4544 JP)</a> (formerly Miraca) and recent Bain PE target <a href="https://www.smartkarma.com/entities/nichii-gakkan-co" target="_blank" data-smartkarma-citation="entities:6790:1" rel="noopener">Nichii Gakkan (9792 JP)</a>.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/706/original/2020-09-14_10-57-45.png?1600048692" class="editor-image img-responsive" data-smartkarma-image-id="158706"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/158/707/original/2020-09-14_10-59-22.png?1600048774" class="editor-image img-responsive" data-smartkarma-image-id="158707"></figure><p>In the <strong>DETAIL</strong> section below, we all review the large companies that have seen the least change in BVPS over the last seven years and those with the lowest BVPS volatility over the same period. Our lists contain quite a few surprises.</p>

Source for all charts &amp; tables except as stated: Japan AnalyticsEQUITY-DRIVEN - Japan's aggregate Shareholders' Equity has appreciated by 45% since 2014 - an annual rate of 5.5% and has been one of the key achievements of the 'Abe era'. For the five years before 2012, Shareholders Equity was unchanged, buffeted by the 2008/9 financial crisis and the 3/11.  Although the equity market has responded well to the change in reserves, Japan's PBR has remained within a range of 1.05 to 1.38 over the last decade and is unchanged compared to 2010. In prior post-bubble 'lost' decades, the average PBR was 1.8 times. In other markets, the rise of intangible assets has called the use of Book/Price as a metric and the S&amp;P 500 PBR is now almost three times that of the Japan aggregate having bottomed at 1.78 in March 2009.Source: multpl.comBOOK VALUE PER SHARE - In this Insight, we shall look at Japan's larger-cap companies (current market value &gt;¥100 billion) through the 'lens' of book value per share. Our focus will be less on the 'winners' and 'losers' than on those companies that have seen the least change in 'BVPS' over the last seven years. Our share count excludes treasury shares which is to the benefit of companies such as NTT (9432 JP) which has seen a 20% reduction in Net Shares Outstanding, but only a 9% increase in Shareholders' Equity. A BVPS growth metric does, however, flatter serial issuers of equity with declining share prices, such as Sosei (4565 JP).WINNERS - As many may ask and for the record, our 'winning' thirty companies contains many of Japan's best-performing businesses and 'priciest 'stocks, such as Monotaro (3064 JP), M3 (2413 JP), GMO Payment Gateway (3769 JP), and Kobe Bussan (3038 JP). Some of the more surprising entries are mixi (2121 JP) and Tokyo Electric Power (9501 JP).  As an equally-weighted portfolio, this group has outperformed by 30% over one year and by 11% over the last three months.LOSERS - Our list of losers, who have collectively underperformed by 9% over one year, have many of Japan's weaker business models (shipping, oil &amp; gas, paper, copiers, gaming machines. The list also features some of the less-astute management 'teams' (Toshiba (6502 JP), Nissan (7201 JP), Kirin (2503 JP), Lixil (5938 JP), and Aeon (8267 JP)).  Also among the latter are two medical-related business - the now remained H.U. Group (4544 JP) (formerly Miraca) and recent Bain PE target Nichii Gakkan (9792 JP).In the DETAIL section below, we all review the large companies that have seen the least change in BVPS over the last seven years and those with the lowest BVPS volatility over the same period. Our lists contain quite a few surprises.

🇯🇵 Japan • Every Shareholder Left Behind - The Book Value Per Share Metric

Japan

M3, Inc. supplies medical information services for doctors through the Internet. The Company also supports marketing of pharmaceutical companies and medical equipment manufacturers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

M3 Inc (2413 JP)

M3 Inc: Strong Earnings Momentum Continues

M3 reported its 2QFY03/21 results which saw both revenue and operating profit grew significantly compared to the same quarter last year by 28.5%...

Shifara Samsudeen, ACMA, CGMA

🇯🇵 JAPAN • Market Update & Results & Revisions 10/30

<¥20T - Aggregate earnings for Japan's listed companies are in their eighth successive quarter of decline. Forecast net income for the year ended...

Campbell Gunn

JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic

JD Health, the largest online retail pharmacy and healthcare platform has filed for an IPO on the HKEX to raise about US$3bn. In this insight, we...

Shifara Samsudeen, ACMA, CGMA

M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic

M3 Inc (2413 JP) provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates...

Shifara Samsudeen, ACMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

M3 Inc: Strong Earnings Momentum Continues

M3 reported its 2QFY03/21 results which saw both revenue and operating profit grew significantly compared to the same quarter last year by 28.5%...

Shifara Samsudeen, ACMA, CGMA

🇯🇵 JAPAN • Market Update & Results & Revisions 10/​​​​​​​​​​​​​​​​​​​​​30

<¥20T - Aggregate earnings for Japan's listed companies are in their eighth successive quarter of decline. Forecast net income for the year ended...

Campbell Gunn

JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic

JD Health, the largest online retail pharmacy and healthcare platform has filed for an IPO on the HKEX to raise about US$3bn. In this insight, we...

Shifara Samsudeen, ACMA, CGMA

M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic

M3 Inc (2413 JP) provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates...

Shifara Samsudeen, ACMA, CGMA

🇯🇵 Japan • Every Shareholder Left Behind - The Book Value Per Share Metric

EQUITY-DRIVEN - Japans

Campbell Gunn

🇯🇵 JAPAN • Market Update & Results & Revisions 10/30